UCL-TRO-1938
Based on 5 publication(s) in Google Scholar
UCL-TRO-1938 is a potent small molecule allosteric activator of PI3Kα with an EC50 value of approximately 60 μM. UCL-TRO-1938 can induce cell proliferation and has cardioprotective effects from ischaemia reperfusion injury and enhances nerve regeneration following nerve crush.
For research use only. We do not sell to patients.
- Purity: 99.98%
- CAS No.: 2919575-27-0
- Formula: C27H32N6O
- Molecular Weight:456.58
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Publications Citing Use of MedChemExpress (MCE) UCL-TRO-1938
More-
Cell Proliferation/Viability Assay
-
Flow Cytometry
Biological Activity
UCL-TRO-1938 (0.01-100 μM, 24 h) induces cell proliferation and induces cell cycle progression in PI3Kα-WT MEFs[1].
UCL-TRO-1938 (1-30 μM, 40 min) induces PI3Kα signalling in a dose- and PI3Kα- dependent manner in rodent and human cells[1].
UCL-TRO-1938 promotes the phosphorylation of Akt S473 in the mimic group in TE-1 and ECA9706 cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:PI3Kα-WT MEFs
-
Concentration:0.01-100 μM
-
Incubation Time:24 h
-
Result:Dose-dependently increased metabolic activity, with an EC50 of ~0.5 μM and decreased the ATP levels in PI3Kα-WT MEFs.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Model of ischaemia reperfusion injury in mice and rat sciatic nerve crush model of peripheral nerve injury and regeneration
-
Dosage:10 mg/kg or 5 μM, 100 μM
-
Administration:i.v., a single dose 15 min prior to reperfusion or a single dose for 21 days
-
Result:Provided substantial tissue protection from IRI, increasing tissue survival and reducing infarct size, and significantly increased neurite outgrowth in dissociated adult rat dorsal root ganglion (DRG) cultures.
Chemical Information
-
CAS No. 2919575-27-0
-
Appearance Solid
-
Molecular Weight 456.58
-
Formula C27H32N6O
-
Color White to off-white
-
SMILES
O=C(C)N1C2=C(CC1)C=CC=C2NC3=CC(NC4=CC=C(N5CCN(CC5)CC)C=C4)=NC=C3
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (5)
-
Journal Impact Factor
-
Most Recent
-
Nat Immunol
2024 Aug;25(8):1422-1431. PMID: 38961274
UCL-TRO-1938 purchased from MedChemExpress. Usage Cited in: Nat Immunol. 2024 Aug;25(8):1422-1431. [Abstract]
Assessment of in-vitro differentiation of primary healthy human peripheral blood pan-B cells into IRF4+ cells with 100 nM dose of PI3Kγi IPI-549 versus DMSO (shown as a proportion) after 5 days in the presence of DMSO control or PI3Kα activator (UCL-TRO-1938 (1 μM; 5 days)).
-
-
Naunyn Schmiedebergs Arch Pharmacol
2026 Apr;399(7):10745-10760. PMID: 41663809 -
bioRxiv
2026 May 12:2026.05.08.723799. PMID: 42182142 -
bioRxiv
2025 May 3:2025.04.29.651098. PMID: 40654790
UCL-TRO-1938 purchased from MedChemExpress. Usage Cited in: bioRxiv. 2025 May 3:2025.04.29.651098. [Abstract]
Line graphs showing the proliferation assay for MCF-10A cells expressing individual FLAG-tagged wild-type or mutant histones assayed using an IncuCyte imaging system. (F) H2B-E76Q, (G) H3-E97K and H3-E105K. Cells were treated with 5 μM of the PI3K activator UCL-TRO-1938 or DMSO vehicle.
Solvent & Solubility
DMSO : 50 mg/mL (109.51 mM; ultrasonic and warming and heat to 80°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.5 mg/mL (5.48 mM); Clear solution; Need ultrasonic
This protocol yields a clear solution of 2.5 mg/mL.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (5.48 mM); Clear solution; Need ultrasonic
This protocol yields a clear solution of 2.5 mg/mL.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (277 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[1]. Gong GQ, et al. A small-molecule PI3Kα activator for cardioprotection and neuroregeneration. Nature. 2023 Jun;618(7963):159-168. [Content Brief]
[2]. Shi H, et al. miR-30c-5p inhibits esophageal squamous cell carcinoma progression by repressing the PI3K/AKT signaling pathway. Thorac Cancer. 2024 Oct;15(30):2206-2216. [Content Brief]
[4]. Kingwell K. PI3K activator taps route to regeneration. Nat Rev Drug Discov. 2023 Jul;22(7):537. [Content Brief]
[5]. Ni C, et al. An inappropriate decline in ribosome levels drives a diverse set of neurodevelopmental disorders. bioRxiv [Preprint]. 2024 Jan 9:2024.01.09.574708. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.1902 mL | 10.9510 mL | 21.9020 mL | 54.7549 mL |
| 5 mM | 0.4380 mL | 2.1902 mL | 4.3804 mL | 10.9510 mL | |
| 10 mM | 0.2190 mL | 1.0951 mL | 2.1902 mL | 5.4755 mL | |
| 15 mM | 0.1460 mL | 0.7301 mL | 1.4601 mL | 3.6503 mL | |
| 20 mM | 0.1095 mL | 0.5475 mL | 1.0951 mL | 2.7377 mL | |
| 25 mM | 0.0876 mL | 0.4380 mL | 0.8761 mL | 2.1902 mL | |
| 30 mM | 0.0730 mL | 0.3650 mL | 0.7301 mL | 1.8252 mL | |
| 40 mM | 0.0548 mL | 0.2738 mL | 0.5475 mL | 1.3689 mL | |
| 50 mM | 0.0438 mL | 0.2190 mL | 0.4380 mL | 1.0951 mL | |
| 60 mM | 0.0365 mL | 0.1825 mL | 0.3650 mL | 0.9126 mL | |
| 80 mM | 0.0274 mL | 0.1369 mL | 0.2738 mL | 0.6844 mL | |
| 100 mM | 0.0219 mL | 0.1095 mL | 0.2190 mL | 0.5475 mL |